CNAT - 4 Healthcare Stocks Seeing Gains On Monday (12/31/18)
CORAL GABLES, FL / ACCESSWIRE / December 31,2018 / The healthcare sector is complex, this much is certain, but amidst the intricacies of the industry exists companies who are determined to innovate towards creating the best quality of care for patients in the space. Companies in the healthcare industry recognize both the importance and cruciality of creating optimal products and services to meet the demands of consumers. Premier Health Group (PHGRF) (PHGI), Aurinia Pharmaceuticals, Inc (NASDAQ: AUPH), Agenus Inc (NASDAQ: AGEN), and Conatus Pharmaceuticals, Inc (NASDAQ: CNAT) are 4 healthcare stocks to pay attention to just before the new year.
Premier Health Group (PHGRF) (PHGI)'s subsidiary, HealthVue, is laser-focused on developing proprietary technology to deliver healthcare through a combination of connected primary care clinics with telemedicine and artificial intelligence. The Company currently boasts a cohesive ecosystem of over 100,000 activepatients, and has plans to rapidly increase its member-base on both a domestic, as well as, global scale. This is wholly in line with the recent trend growing within healthcare which has seen companies look for new connected technology.
Premier Health Group (PHGRF) (PHGI) announced earlier this month that, in an effort to stay competitive with other companies in the healthcare sector, it signed a binding Letter of Intent agreement to acquire a Vancouver-based pharmacy. According to details regarding the agreement, Premier expects the acquisition of the pharmacy to close in or around Q1-19. In addition to this news, the Company has made it a priority to collaborate with telehealth tech experts to build out its immensely successful HealthVue app, which enables patients to access primary care physicians remotely through the use of a smartphone app.
"We are excited for this opportunity to acquire our first pharmacy, and thereafter being able to prepare and deliver prescription and non-prescription pharmaceuticals and other health products to patients. In doing so, the pharmacist will play an integral role in our team-based patient centric model," said Dr. Essam Hamza, CEO of Premier. "Premier has engaged with patients, pharmacies and technology providers to not only introduce pharmacy services as a component of our comprehensive telemedicineapp,but also to explore and implement efficienciesin fill and fulfillment."
For More Information On Premier Health Group, Click Here
Aurinia Pharmaceuticals, Inc (AUPH) announced, at the tail-end of November, that it had entered into an Open Market Sale Agreement with Jeffries LCC pursuant to which the Company may, from time to time sell, through at-the-market offerings with Jeffries acting as a sales agent or directly to Jeffries acting as principal, such common shares in the capital of the Company as would have an aggregate offering price of up to $30 million.
In addition to this announcement, stated in an official press release from the Company, Aurinia has also filed a prospectus supplement with securities regulatory authorities in Canada, and with the US Securities and Exchange Commission.
For More Information On Aurinia Pharmaceuticals, Inc, Click Here
Agenus, Inc (AGEN) announced late last week that it would be entering into an immuno-oncology partnership with Gilead Sciences, Inc, with their collaborative efforts focused on the development and commercialized of up to five new immuno-oncology therapies. According to their official announcement, the Company will receive $150 million upon closing, which includes a $120 million upfront cash payment and a $30 million equity investment. The agreement also includes approximately $1.7 billion in potential future fees and milestones.
Per the press release at the time, Garo Armen, Chairmanand CEO of Agenus, said, ''Gilead is an ideal partner for Agenus for the rapid advancement of our pipeline. By year end, our discovery platforms will have resulted in six INDs in 2018 and 13 INDs by the 1H2019. Gilead's established global presence and commitment to disruptive therapies, combined withour track-record in building a broad pipeline in I-O, has the potential to yield breakthrough I-O treatments for patients with cancer.''
For More Information on Agenus, Inc, Click Here
Conatus Pharmaceuticals Inc (CNAT) made headlines earlier this month when the Company announced its recent results regarding their Phase 2b ENCORE-PH clinical trial showing clinically meaningful treatment effects in compensated NASH cirrhosis patients at high risk of decompensation.
According to the press release, Dr. Guadalupe Garcia-Tsao,central reader for the Company's recent clinical trial, "We have recently shown that the risk of decompensation and death rises with progressive increases in HVPG. Conversely, reductions in HVPG as small as 1 mmHg can reduce the risk of decompensation or death. Post-hoc analyses from the ENCORE-PH trial showing that, compared to placebo, emricasan is associated with clinically meaningful incremental reductions in HVPG with worsening baseline HVPG levels, strongly suggest that emricasan has the potential of providing patient benefit."
For More Information On Conatus Pharmaceuticals, Inc, Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We were paid an additional $100,000 (CASH) for continued coverage. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6)Six month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
Contact Information:
SOURCE: StockPrice.com